使用伐尼克兰进行为期十二周的戒烟治疗，仅在成功戒烟组中提高了血清载脂蛋白A-I水平。

Twelve weeks of smoking cessation therapy with varenicline increases the serum levels of apolipoprotein A-I only in the success group.

作者信息

Iwaoka Masahiko, Shimamura Hiromasa, Tsuji Takeshi, Kugiyama Kiyotaka

机构信息

Division of Cardiology, Tokyo Kita Social Insurance Hospital, Tokyo, Japan.

出版信息

J Cardiol. 2014 Oct;64(4):318-23. doi: 10.1016/j.jjcc.2014.02.009. Epub 2014 Mar 24.

DOI:10.1016/j.jjcc.2014.02.009

PMID:24674749

Abstract

BACKGROUND

Cigarette smoking adversely affects lipid profiles, and smoking cessation should improve lipid profiles in the long term. However, it remains unclear whether intensive, medication-based smoking cessation therapy can affect lipid profiles in the short term. Thus, we evaluated the short-term effects of smoking cessation therapy with varenicline on lipid profiles.

METHODS

Participants included 86 consecutive subjects who received 12 weeks of smoking cessation therapy. All subjects were treated with varenicline, and no changes were made to their current lipotropic and antidiabetic medications during treatment. At first and last visits, lipid profiles and fasting blood glucose and hemoglobin A1c levels were evaluated and physical examination was performed. The success group, comprising subjects who attained exhaled carbon monoxide-confirmed 4-week continuous abstinence, included 69 subjects, whereas the failure group, comprising those who did not achieve complete smoking cessation, included 17 subjects. The number of cigarettes consumed per day was reduced in all subjects in the failure group.

RESULTS

Serum apolipoprotein A-I (apoA-I) and high-density lipoprotein cholesterol (HDL-C) levels significantly increased from baseline to 12 weeks in the success group (apoA-I: 151.7 ± 28.0 vs. 158.6 ± 27.3 mg/dL, respectively, p<0.01; HDL-C: 54.6 ± 15.7 vs. 57.9 ± 14.3 mg/dL, respectively, p<0.01); however, there were no statistically significant differences observed in the failure group (apoA-I, 145.9 ± 33.4 vs. 146.8 ± 34.2 mg/dL, respectively, p=0.87; HDL-C, 52.6 ± 15.7 vs. 53.3 ± 16.3 mg/dL, respectively, p=0.80). The effect sizes (Cohen's d) of apoA-I and HDL-C in the success group were 0.42 and 0.46, respectively. The post hoc statistical power values of apoA-I and HDL-C in the success group were 0.94 and 0.96, respectively.

CONCLUSION

These findings suggest that successful smoking cessation therapy with varenicline improves serum apoA-I and HDL-C levels in the short term.

摘要

背景

吸烟对血脂水平有不利影响，长期戒烟应可改善血脂水平。然而，基于药物的强化戒烟疗法在短期内是否会影响血脂水平仍不清楚。因此，我们评估了伐尼克兰戒烟疗法对血脂水平的短期影响。

方法

参与者包括86名连续接受12周戒烟治疗的受试者。所有受试者均接受伐尼克兰治疗，治疗期间其当前的促脂药物和抗糖尿病药物均未改变。在首次和末次就诊时，评估血脂水平、空腹血糖和糖化血红蛋白水平，并进行体格检查。成功组包括经呼出一氧化碳确认连续4周戒烟的受试者，共69名；失败组包括未完全戒烟的受试者，共17名。失败组所有受试者的每日吸烟量均有所减少。

结果

成功组血清载脂蛋白A-I（apoA-I）和高密度脂蛋白胆固醇（HDL-C）水平从基线至12周显著升高（apoA-I分别为151.7±28.0与158.6±27.3mg/dL，p<0.01；HDL-C分别为54.6±15.7与57.9±14.3mg/dL，p<0.01）；然而，失败组未观察到统计学显著差异（apoA-I分别为145.9±33.4与146.8±34.2mg/dL，p=0.87；HDL-C分别为52.6±15.7与53.3±16.3mg/dL，p=0.80）。成功组apoA-I和HDL-C的效应量（科恩d值）分别为0.42和0.46。成功组apoA-I和HDL-C的事后统计检验效能值分别为0.94和0.96。